Abstract: The invention discloses treatment and reuse of oilfield produced water. A method of inhibiting enzymes/bacteria in an aqueous medium for viscosification comprises contacting the aqueous medium with a denaturant and/or a bactericide and thereafter mixing a gelling agent in the aqueous medium. The viscosified fluid can be used as a well treating fluid for fracturing and other applications. A well treatment fluid comprises a metal denaturant and/or a bactericide and a gelling agent in an amount effective to viscosify the fluid. Also disclosed is oilfield produced water denatured with from 1 to 2000 ppm by weight of a zirconium compound.

Abstract: This invention provides compounds defined by Formula I or a pharmaceutically acceptable salt thereof, wherein R1, Q, Y1, Y2, Y3, and R2 are as defined in the specification. The invention also provides pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, as defined in the specification, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of inhibiting an MMP-13 enzyme in an animal, comprising administering to the animal a compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention also provides methods of treating a disease mediated by an MMP-13 enzyme in a patient, comprising administering to the patient a compound of Formula I, or a pharmaceutically acceptable salt thereof, either alone or in a pharmaceutical composition.

Abstract: The present invention is directed to a beverage container with nubs and a method for producing such beverage containers with nubs.

Abstract: This invention provides compounds defined by Formula I 1

Abstract: This invention provides compounds defined by Formula I 1

Abstract: A compound selected from those of formula (I): 1

Abstract: Quinoxaline compounds are described as well as methods for the preparation and pharmaceutical compositions of same, which are useful as interleukin-8 (IL-8) receptor antagonists and can be used in the treatment of a chemokine-mediated disease wherein the chemokine binds to an IL-8a (CXCR1) or b (CXCR2) receptor such as a chemokine-mediated disease selected from psoriasis, or atopic distress syndrome, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, septic shock, endotoxic shock, gram-negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulo-nephritis, or thrombosis, Alzheimer's disease, graft versus host reaction, allograft rejections, or allergic diseases.

Abstract: Selective MMP-13 inhibitors are fused pyrimidinones of the formula 1

Abstract: The present invention discloses a system for adaptively reducing flickers in converting non-interlaced video signals to interlaced video signals. To preserve the original image quality in the non-interlaced video signals, the disclosed system examines the pixel values in at least two adjacent lines to decide if a reduction process should be turned on. If there is a need, the reduction process further examines the difference in the pixels from the adjacent lines to determine how to adjust a corresponding output to eliminate flickers in the resultant converted video signals. The adjusting means is based on an adjusting factor or the calculated difference between pixels which is further used in a function to eventually produce a converted interlaced signal with minimum visual errors.